Search Results - "Juergen Grote, Hans"

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial by Gulley, James L, Dr, Rajan, Arun, MD, Spigel, David R, MD, Iannotti, Nicholas, MD, Chandler, Jason, MD, Wong, Deborah J L, MD, Leach, Joseph, MD, Edenfield, W Jeff, MD, Wang, Ding, MD, Grote, Hans Juergen, MD, Heydebreck, Anja von, PhD, Chin, Kevin, MD, Cuillerot, Jean-Marie, MD, Kelly, Karen, MD

“…Summary Background Avelumab, a human Ig-G1 monoclonal antibody targeting PD-L1 and approved in the USA for the treatment of metastatic Merkel cell carcinoma,…”
Get full text

PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters by Silva, Manuel A, Ryall, Karen A, Wilm, Claudia, Caldara, Jenifer, Grote, Hans Juergen, Patterson-Kane, Janet C

“…Non-Small Cell Lung Cancer (NSCLC) is the leading cause of cancer death globally, and new immunotherapies developed and under development targeting PD-1/PD-L1…”
Get full text

Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors by Goodman, Simon L, Grote, Hans Juergen, Wilm, Claudia

“…The relationship between integrin expression and function in pathologies is often contentious as comparisons between human pathological expression and…”
Get full text

Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study by Verschraegen, Claire F, Jerusalem, Guy, McClay, Edward F, Iannotti, Nicholas, Redfern, Charles H, Bennouna, Jaafar, Chen, Franklin L, Kelly, Karen, Mehnert, Janice, Morris, John C, Taylor, Matthew, Spigel, David, Wang, Ding, Grote, Hans Juergen, Zhou, Dongli, Munshi, Neru, Bajars, Marcis, Gulley, James L

“…IntroductionAvelumab, an antiprogrammed death ligand-1 antibody, is approved as a monotherapy for treatment of metastatic Merkel cell carcinoma and advanced…”
Get full text

1283 A novel, scalable deep learning-based approach to automated quality control of multiplex immunofluorescence images by Fink, Annika F, Schulte-Sasse, Roman, Bauw, Martin, Agrawal, Deepti, Perez, Beatriz, Sadeq, Mariam, Grote, Hans Juergen, Ohata, Yae, Ruff, Lukas, Alber, Maximilian, Ruane, Sharon, Mrowiec, Thomas

“…BackgroundMultiplex immunofluorescence (mIF) imaging allows identification of multiple protein markers on the same tissue section at cell-level resolution…”
Get full text

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial by Guigay, Joël, Lee, Keun-Wook, Patel, Manish R, Daste, Amaury, Wong, Deborah J, Goel, Sanjay, Gordon, Michael S, Gutierrez, Martin, Balmanoukian, Ani, Le Tourneau, Christophe, Mita, Alain, Vansteene, Damien, Keilholz, Ulrich, Schöffski, Patrick, Grote, Hans Juergen, Zhou, Dongli, Bajars, Marcis, Penel, Nicolas

“…BackgroundRecurrent and/or metastatic (R/M) disease develops in approximately 65% of patients with squamous cell carcinoma of the head and neck (SCCHN) and is…”
Get full text

9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA‐ICM, and AgNOR analysis by Onofre, Fabiana Botelho de Miranda, Onofre, Alexandre Sherlley Casimiro, Pomjanski, Natalia, Buckstegge, Birgit, Grote, Hans Juergen, Böcking, Alfred

“…BACKGROUND The diagnosis of malignant mesothelioma (MM) in serous effusions is difficult but may be achieved by the application of adjuvant methods. METHODS…”
Get full text

Methylation Assay for the Diagnosis of Lung Cancer on Bronchial Aspirates: A Cohort Study by SCHMIEMANN, Viola, BOCKING, Alfred, KAZIMIREK, Marietta, CASIMIRO ONOFRE, Alexandre Sherlley, GABBERT, Helmut Erich, KAPPES, Rainer, GERHARZ, Claus Dieter, GROTE, Hans Juergen

“…Purpose: Recent studies have detected aberrant promoter methylation of adenomatous polyposis coli promoter 1 A ( APC ), cyclin-dependent kinase inhibitor-2A (…”
Get full text

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy by Gulley, James L., Spigel, David, Kelly, Karen, Chandler, Jason Claud, Rajan, Arun, Hassan, Raffit, Wong, Deborah Jean Lee, Leach, Joseph, Edenfield, William Jeffery, Wang, Ding, Vrindavanam, Nandagopal, Weiss, Glen J., Gurtler, Jayne S., Grote, Hans Juergen, von Heydebreck, Anja, Chin, Kevin M., Iannotti, Nicholas

“…Abstract only…”
Get full text

Methylation of RAS association domain family protein 1A as a biomarker of lung cancer by Grote, Hans Juergen, Schmiemann, Viola, Geddert, Helene, Bocking, Alfred, Kappes, Rainer, Gabbert, Helmut Erich, Sarbia, Mario

“…BACKGROUND Promoter hypermethylation is an important mechanism for silencing tumor‐suppressor genes in cancer and a promising tool for development of molecular…”
Get full text

Immunocytochemical identification of carcinomas of unknown primary in serous effusions by Pomjanski, Natalia, Juergen Grote, Hans, Doganay, Peyrüze, Schmiemann, Viola, Buckstegge, Birgit, Böcking, Alfred

“…Metastases from carcinomas of unknown primary site (CUP) in serous effusion are a common clinical problem. Immunocytochemistry was applied as an adjunct to the…”
Get full text

In situ detection of global DNA hypomethylation in exfoliative urine cytology of patients with suspected bladder cancer by Seifert, Hans-Helge, Schmiemann, Viola, Mueller, Mirko, Kazimirek, Marietta, Onofre, Fabiana, Neuhausen, Anne, Florl, Andrea R., Ackermann, Rolf, Boecking, Alfred, Schulz, Wolfgang A., Grote, Hans Juergen

“…Global DNA hypomethylation is a common phenomenon in bladder cancer. Therefore we investigated whether it is possible to detect and assess global DNA…”
Get full text

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study by Dirix, Luc Y., Takacs, Istvan, Jerusalem, Guy, Nikolinakos, Petros, Arkenau, Hendrik-Tobias, Forero-Torres, Andres, Boccia, Ralph, Lippman, Marc E., Somer, Robert, Smakal, Martin, Emens, Leisha A., Hrinczenko, Borys, Edenfield, William, Gurtler, Jayne, von Heydebreck, Anja, Grote, Hans Juergen, Chin, Kevin, Hamilton, Erika P.

“…Purpose Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have shown antitumor activity in the treatment of metastatic breast cancer…”
Get full text

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial by Disis, Mary L, Taylor, Matthew H, Kelly, Karen, Beck, J Thaddeus, Gordon, Michael, Moore, Kathleen M, Patel, Manish R, Chaves, Jorge, Park, Haeseong, Mita, Alain C, Hamilton, Erika P, Annunziata, Christina M, Grote, Hans Juergen, von Heydebreck, Anja, Grewal, Jaspreet, Chand, Vikram, Gulley, James L

“…Current treatment options for progressive ovarian cancer provide limited benefit, particularly in patients whose disease has become resistant to platinum-based…”
Get more information

Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay by Grote, Hans Juergen, Feng, Zheng, Schlichting, Michael, Helwig, Christoph, Ruisi, Mary, Jin, Hulin, Scheuenpflug, Juergen, Gann, Claudia-Nanette, Su, Zhen, Reck, Martin, Vokes, Everett E, Kerr, Keith M

“…Several programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays have been developed independently within clinical programs for therapeutic…”
Get more information

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial by Hassan, Raffit, Thomas, Anish, Nemunaitis, John J, Patel, Manish R, Bennouna, Jaafar, Chen, Franklin L, Delord, Jean-Pierre, Dowlati, Afshin, Kochuparambil, Samith T, Taylor, Matthew H, Powderly, John D, Vaishampayan, Ulka N, Verschraegen, Claire, Grote, Hans Juergen, von Heydebreck, Anja, Chin, Kevin, Gulley, James L

“…Patients with malignant mesothelioma whose disease has progressed after platinum and pemetrexed treatment have limited options. Anti-programmed cell death 1…”
Get more information

Comparative study of two PD-L1 expression assays in patients with non-small cell lung cancer (NSCLC) by Feng, Zheng, Schlichting, Michael, Helwig, Christoph, Chand, Vikram K., Gelb, Arnold, Jin, Hulin, Grote, Hans Juergen

“…Abstract only e20581 Background: Response to anti–PD-L1/PD-1 therapy in patients with NSCLC has been associated with tumor PD-L1 expression. Avelumab is a…”
Get full text

Digital pathology to evaluate PD-L1 IHC scoring as a predictor of outcome with second-line avelumab treatment in patients with non-small cell lung cancer (NSCLC) by Mrowiec, Thomas, Svenson, Elena, Gerhold-Ay, Aslihan, Wolf, Corinna M, Grote, Hans Juergen, Otte, Marcus, Rolfe, P. Alexander, Shah, Parantu K., von Heydebreck, Anja, Scheuenpflug, Juergen, Ruisi, Mary M., Labarta-Beceiro, Violeta, Beeman, Glenn, Cai, Ti

“…Abstract only e21539 Background: Assessment of programmed death ligand-1 (PD-L1) protein expression using immunohistochemistry (IHC)-based tests is currently…”
Get full text

Exploratory biomarker analysis in avelumab-treated patients with metastatic Merkel cell carcinoma progressed after chemotherapy by Shapiro, Irina, Grote, Hans Juergen, D'Urso, Vittorio, von Heydebreck, Anja, Mahnke, Lisa, Kaufman, Howard, Nghiem, Paul, Cai, Ti

“…Abstract only 9557 Background: Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer. Tumor oncogenesis is linked to Merkel cell polyomavirus…”
Get full text

Avelumab (anti–PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial by Rajan, Arun, Gulley, James L., Spigel, David R., Iannotti, Nicholas, Chandler, Jason Claud, Wong, Deborah J.L., Leach, Joseph W., Edenfield, William Jeffery, Wang, Ding, Redfern, Charles H., Grote, Hans Juergen, von Heydebreck, Anja, Ruisi, Mary M., Munshi, Neru, Kelly, Karen

“…Abstract only…”
Get full text